GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Price-to-Funds-From-Operations

Contineum Therapeutics (Contineum Therapeutics) Price-to-Funds-From-Operations : (As of Jun. 02, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Contineum Therapeutics (Contineum Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.